List of Supprelin La drug patents

Supprelin La is owned by Endo Pharm.

Supprelin La contains Histrelin Acetate.

Supprelin La has a total of 1 drug patent out of which 0 drug patents have expired.

Supprelin La was authorised for market use on 03 May, 2007.

Supprelin La is available in implant;subcutaneous dosage forms.

Supprelin La can be used as method of treatment of children with central precocious puberty.

The generics of Supprelin La are possible to be released after 16 June, 2026.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8062652 ENDO PHARM Compositions and methods for treating precocious puberty
Jun, 2026

(3 years from now)

Drugs and Companies using HISTRELIN ACETATE ingredient

Market Authorisation Date: 03 May, 2007

Treatment: Method of treatment of children with central precocious puberty

Dosage: IMPLANT;SUBCUTANEOUS

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in